ClinicalTrials.gg
CompletedNCT00309777Updated Jan 12, 2010Results posted

Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin

A Phase 3 interventional study of Pitavastatin and Simvastatin in Hypercholesterolemia and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-01-12.

Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
857
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
3rd of 19
857 · median 200
Started
2005
with 4 others
Phase 3
9 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
7 of 19
Kowa Research Europe

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 3rd largest by enrollment, is one of 5 that started in 2005, is one of 9 in phase 3, and was the 3rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin.

03

Conditions studied

  • Hypercholesterolemia
  • Dyslipidemia

Keywords

  • hypercholesterolemia
  • kowa
  • dyslipidemia
  • pitavastatin
  • NK-104
  • Primary Hypercholesterolemia or Combined Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females (18-75 years)
  • Must have been following a restrictive diet
  • Diagnosis of primary hypercholesterolemia or combined dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia;
  • Conditions which may cause secondary dyslipidemia.
  • Uncontrolled diabetes mellitus (by [HbA1c] > 8%)
  • Abnormal serum creatine kinase (CK) above the pre-specified level
  • Abnormal pancreatic, liver or renal function
  • Significant heart disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
857 participants (actual)

Study arms

  • Experimental
    Pitavastatin 2 mg

    Pitavastatin 2 mg once daily

    Drug: Pitavastatin

  • Active comparator
    Simvastatin 20 mg

    Simvastatin 20 mg once daily

    Drug: Simvastatin

  • Experimental
    Pitavastatin 4 mg

    Pitavastatin 4 mg once daily

    Drug: Pitavastatin

  • Active comparator
    Simvastatin 40 mg

    Simvastatn 40 mg once daily

    Drug: Simvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks

    Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)after 12 Weeks

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. National Cholesterol Education Program (NCEP) LDL-C Target Attainment

    Number of subjects achieving National Cholesterol Education Program (NCEP) LDL-C Target (LDL less than or equal to 130 mg/dL)at Week 12

    Time frame: 12 week

07

Results

Posted Dec 16, 2009

Participant flow

Subjects were randomized to one of 4 treatment arms based on inclusion/exclusion criteria.

Participant flow — Overall Study
MilestonePitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mg
Started315108323111
Safety population311107320110
Completed29299304107
Not completed239194
Withdrew: Adverse event13281
Withdrew: Protocol violation4131
Withdrew: Withdrawal by subject6572
Withdrew: Lost to follow-up0010
Withdrew: Death0100

Outcome measures

PrimaryPercent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks

Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)after 12 Weeks

Time frame:
Baseline to 12 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks
Percent changePitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mg
Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks-38.99 ± 14.573-34.97 ± 15.528-43.97 ± 14.494-42.84 ± 15.769
SecondaryNational Cholesterol Education Program (NCEP) LDL-C Target Attainment

Number of subjects achieving National Cholesterol Education Program (NCEP) LDL-C Target (LDL less than or equal to 130 mg/dL)at Week 12

Time frame:
12 week
Reported as:
Number · Participants
National Cholesterol Education Program (NCEP) LDL-C Target Attainment
ParticipantsPitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mg
National Cholesterol Education Program (NCEP) LDL-C Target Attainment2156925386

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 2 mg—3/311 (1%)56/311 (18%)
Simvastatin 20 mg—2/107 (1.9%)28/107 (26.2%)
Pitavastatin 4 mg—4/320 (1.3%)44/320 (13.8%)
Simvastatin 40 mg—2/110 (1.8%)10/110 (9.1%)
Most frequent serious events
Most frequent serious events
EventPitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mg
ErysipelasInfections and infestations0/3110/1070/3202/110
Atrial fibrillationCardiac disorders0/3111/1070/3200/110
Sudden cardiac deathGeneral disorders0/3111/1070/3200/110
PleuropericarditisCardiac disorders1/3110/1070/3200/110
Pancreatitis acuteGastrointestinal disorders1/3110/1070/3200/110
Anaphylactic reationImmune system disorders1/3110/1070/3200/110
Non-cardiac chest painGeneral disorders0/3110/1071/3200/110
Campylobacter intestinal infectionInfections and infestations0/3110/1071/3200/110
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3110/1071/3200/110
ConvulsionNervous system disorders0/3110/1071/3200/110
Most frequent other events
Most frequent other events
EventPitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mg
InfluenzaInfections and infestations4/3116/1071/3201/110
ArthralgiaMusculoskeletal and connective tissue disorders4/3115/1073/3200/110
HeadacheNervous system disorders10/3114/10711/3202/110
MyalgiaMusculoskeletal and connective tissue disorders9/3113/1076/3203/110
Back painMusculoskeletal and connective tissue disorders3/3113/1077/3201/110
NauseaGastrointestinal disorders4/3113/1076/3201/110
DiarrheaGastrointestinal disorders8/3112/1076/3201/110
Upper respiratory tract infectionInfections and infestations7/3111/1073/3201/110
FatigueGeneral disorders7/3111/1071/3200/110

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mgTotal
<=18 years00000
Between 18 and 65 years2147223176593
>=65 years97358934255
Age Continuous
Age Continuous(years)Pitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mgTotal
Mean58.7 ± 8.8358.6 ± 9.6457.7 ± 8.9758.4 ± 9.5458.3 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 2 mgSimvastatin 20 mgPitavastatin 4 mgSimvastatin 40 mgTotal
Female1966319548502
Male1154412562346
08

Study locations

42 sites
  • Geri-Med Oy
    Helsinki, Finland
  • Kaisaniemen Laakariasema
    Helsinki, Finland
  • Keravan Laakarikeskus
    Helsinki, Finland
  • SOK-tyoterveyshuolto
    Tampere, Finland
  • TYKS University Hospital
    Turku, Finland
  • Dipartimento Di Medicina Clinica e Biotecnologia Applicata
    Bologna, Italy
  • Centro di Ricerca Clinica
    Chieti, Italy
  • Gerontologia e Geriatria - Universita degli Studi
    Ferrara, Italy
  • Dipartimento di Medicina Interna DIMI
    Genova, Italy
  • Universita di Modena e Reggio Emilia, Policlinico
    Modena, Italy
  • Dipartimento di Medicina Clinica e Sperimentale
    Napoli, Italy
  • Medicina Clinica e delle Patologie Emergenti
    Palermo, Italy
  • Dipartimento di Medicina Interna e Scienze Biomediche
    Parma, Italy
  • U.O Malattie Metaboliche e Diabetologia
    Treviglio, Italy
  • Azienda Ospedaliero-Universitaria
    Trieste, Italy
  • Volvat Medisinske Senter
    Fredrikstad, Norway
  • Nyomen Legekontor
    Kongsberg, Norway
  • Radhuset Spesialistsenter
    Oslo, Norway
  • Rikshospitalet - University Hospital
    Oslo, Norway
  • Skedsmo Medisinske Senter A.S.
    Skedsmokorset, Norway
  • Kemerovo Cardiology Dispensary
    Kemerovo, Russian Federation
  • Central Clinical Hospital 1 of RZD
    Moscow, Russian Federation
  • City Clinical Hospital 23
    Moscow, Russian Federation
  • City Clinical Hospital 64
    Moscow, Russian Federation
  • Moscow City Clinical Hospital 68
    Moscow, Russian Federation
  • State Research Center for Preventive Medicine
    Moscow, Russian Federation
  • Novosibirsk Reg. Clinical Cardiology Dispensary
    Novosibirsk, Russian Federation
  • Central Medical Unit 122, St. Pb
    Saint Petersburg, Russian Federation
  • Clinical Hospital of Russian Academy of Sciences
    Saint Petersburg, Russian Federation
  • Consulting and Diagnostic Center 85
    Saint Petersburg, Russian Federation
  • Krestovsky Island Medical Institute
    Saint Petersburg, Russian Federation
  • Pokrovskaya City Hospital
    Saint Petersburg, Russian Federation
  • St Michael's Partnership
    Bath, United Kingdom
  • Avondale Surgery
    Chesterfield, United Kingdom
  • Knowle House Surgery
    Plymouth, United Kingdom
  • The Burngreave Surgery
    Sheffield, United Kingdom
  • St Helier Hospital
    Surrey, United Kingdom
  • Box Surgery
    Wiltshire, United Kingdom
  • Eastleigh Surgery
    Wiltshire, United Kingdom
  • Lovemead Group Practice
    Wiltshire, United Kingdom
  • St Chad's Surgery
    Wiltshire, United Kingdom
  • The Health Centre
    Wiltshire, United Kingdom
09

References and documents

Publications

  • Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009 Nov;25(11):2755-64. doi: 10.1185/03007990903290886. Erratum In: Curr Med Res Opin. 2010 May;26(5):1046. Dosage error in article text. PubMed 19785568 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2005
First posted
Apr 3, 2006
Start
Sep 2005
Primary completionActual
Oct 2006
CompletionActual
Oct 2006
Results first posted
Dec 16, 2009
Last update
Jan 12, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00309777
First posted
Apr 3, 2006
Start date
Sep 2005
Primary completion
Oct 2006
Completion
Oct 2006
Results posted
Dec 16, 2009
Last update
Jan 12, 2010

Study contacts

Dragos Budinski, Med Dr.
study director · Medical Director

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion